ZYMEZymeworks Inc.
Pharmaceutical Preparations
- Revenue
- $106M
- 39% YoY
- Operating margin
- -87.3%
- 51% YoY
- EBITDA
- −$89M
- 33% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired26% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-126% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear3% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $27M | $412M | $76M | $76M | $106M | 39% |
| Operating income | −$216M | $131M | −$138M | −$137M | −$93M | 33% |
| Net income | −$212M | $124M | −$119M | −$123M | −$81M | 34% |
| Operating cash flow | −$192M | $144M | −$118M | −$110M | −$33M | 70% |
| Capex | $12M | $8M | $2M | $2M | $2M | 24% |
| Stock-based comp | $11M | $4M | $8M | $18M | $28M | 58% |
| Buybacks | — | $0 | $0 | $30M | $42M | 39% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $358K · 1
- Net
- −$358K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 335 | — |
| FY2024 | — | — | 186 | — |
| FY2023 | — | — | 132 | — |